
Adani Power, LIC, Divi’s Laboratories, Hindustan Aeronautics, Adani Green Energy and others have high market capitalisation compared to the NIFTY50 bottom five stocks. But despite this, the stock is not part of the NIFTY50 index. Here’s why
as of 21/11/2026, 2:36:58 pm
02/Price history
1 year · daily candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.
| 20 Nov 2026 | 1,418.50 | 1,428.00 | 1,401.20 | 1,415.00 | -0.25% | 26.80 | 14.84 L |
| 19 Nov 2026 | 1,420.00 | 1,427.50 | 1,406.70 | 1,418.50 | -0.11% | 20.80 | 19.97 L |
| 18 Nov 2026 | 1,390.00 | 1,435.00 | 1,381.30 | 1,417.00 | +1.94% | 53.70 | 29.09 L |
| 17 Nov 2026 | 1,390.00 | 1,399.40 | 1,383.00 | 1,388.00 | -0.14% | 16.40 | 10.17 L |
| 16 Nov 2026 | 1,393.00 | 1,406.00 | 1,389.00 | 1,394.50 | +0.11% | 17.00 | 12.49 L |
| 13 Nov 2026 | 1,407.00 | 1,418.70 | 1,391.80 | 1,391.80 | -1.08% | 26.90 | 10.23 L |
| 12 Nov 2026 | 1,413.60 | 1,420.00 | 1,399.50 | 1,408.30 | -0.37% | 20.50 | 16.84 L |
| 11 Nov 2026 | 1,415.80 | 1,420.20 | 1,406.10 | 1,419.90 | +0.29% | 14.10 | 17.23 L |
| 9 Nov 2026 | 1,408.00 | 1,421.40 | 1,397.50 | 1,403.80 | -0.30% | 23.90 | 17.06 L |
| 8 Nov 2026 | 1,414.50 | 1,416.00 | 1,405.00 | 1,405.80 | -0.62% | 11.00 | 65.3K |
Historical price and volume data · Showing 1–10 of 248
03/Valuation & returns
Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.
Price ÷ earnings per share
Worse than sector by 189%
Price ÷ book value per share
Better than sector by 23%
Net income ÷ total assets
Better than sector by 455%
Net income ÷ shareholders' equity
Better than sector by 2145%
EBIT ÷ capital employed
Worse than sector by 30%
Liquid assets ÷ current liabilities
Worse than sector by 48%
Enterprise value ÷ EBITDA
Better than sector by 5%
04/Business
Sector: Pharmaceuticals
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
reported in crore
reported in billion
Market capitalisation is reported at the sector-constituent level, not the standalone company level.
05/Profit & loss
Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.
| Revenue | 7,555 | 7,330 | 6,689 | 7,281 |
|---|---|---|---|---|
| Revenue growthreported | 3.1% | 9.6% | -8.1% | — |
| Operating profit | 1,177 | 1,082 | 707 | 893 |
| Operating profit growthreported | 8.8% | 53.0% | -20.8% | — |
| Operating marginderived | 15.6% | 14.8% | 10.6% | 12.3% |
| Net profit | 857 | 787 | 550 | 675 |
| Net profit growthreported | 8.8% | 43.1% | -18.4% | — |
| Net marginderived | 11.3% | 10.7% | 8.2% | 9.3% |
| EPS — basic₹/share, annual | — | — | 48.03 | — |
Figures in ₹ crore. Margin rows are computed from the reported values.
06/Balance sheet
Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.
| Total assets | 42,496 | 37,387 | 32,718 | 29,463 |
|---|---|---|---|---|
| Total liabilities | 7,976 | 6,098 | 5,915 | 5,750 |
| Net worthderived | 34,520 | 31,289 | 26,802 | 23,714 |
| Liabilities ÷ assetsderived | 18.8% | 16.3% | 18.1% | 19.5% |
| Asset growthderived | 13.7% | 14.3% | 11.0% | — |
Figures in ₹ crore. Stacked chart height equals total assets.
| Non-Current Assets | 18,350 | 14,138 | 13,325 | 12,658 |
|---|---|---|---|---|
| Current Assets | 24,146 | 23,249 | 19,392 | 16,805 |
| Total Assets | 42,496 | 37,387 | 32,718 | 29,463 |
| Current Liabilities | 7,014 | 5,484 | 5,246 | 5,110 |
| Net Current Asset | 17,132 | 17,765 | 14,147 | 11,695 |
| Non-Current Liabilities | 962 | 614 | 670 | 640 |
| Equity Capital | 34,520 | 31,289 | 26,802 | 23,714 |
| Total Equity & Liabilities | 42,496 | 37,387 | 32,718 | 29,463 |
Figures in ₹ crore unless the line item is per-share.
07/Cash flow
Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.
| Operating activities | 3,940 | 5,005 | 4,134 | 3,238 |
|---|---|---|---|---|
| Operating changereported | -21.3% | 21.1% | 27.7% | — |
| Investing activities | -2,326 | -3,691 | -2,988 | -2,389 |
| Investing changereported | 37.0% | -23.5% | -25.1% | — |
| Financing activities | -1,234 | -1,293 | -1,200 | -958 |
| Financing changereported | 4.6% | -7.7% | -25.3% | — |
| Net cash flowderived | 380 | 21 | -55 | -109 |
| Free cash flowoperating + investing | 1,614 | 1,314 | 1,146 | 849 |
Figures in ₹ crore.
| Profit before tax | 5,224 | 6,821 | 5,897 | 4,221 |
|---|---|---|---|---|
| Income before WC changes | 5,751 | 7,339 | 6,537 | 5,099 |
| Change in Assets | -878 | -1,065 | -969 | -541 |
| Change in Liabilities | 653 | 400 | 163 | -18 |
| Change in WC | -225 | -665 | -806 | -559 |
| Cash flow from Operations | 3,940 | 5,005 | 4,134 | 3,238 |
| Cash flow from Investing | -2,326 | -3,691 | -2,988 | -2,389 |
| Cash flow from Financing | -1,234 | -1,293 | -1,200 | -958 |
| Total Cash Flow | 380 | 21 | -55 | -109 |
| Cash (Start of the year) | 543 | 512 | 561 | 658 |
| Cash (End of the year) | 1,015 | 543 | 512 | 561 |
Figures in ₹ crore unless the line item is per-share.
09/Events
Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.
| DividendFinal | ₹13.00 | 650.0% | 05 Jun 2026 | 05 Jun 2026 | 13 May 2026 |
10/Comparison
Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.
| SUNPHARMASUN Pharmaceutical IND L | Pharmaceuticals | ₹1,884.90 | -0.79% | 19.16 L | ₹4,52,299 Cr | $50.26B | |
| DIVISLABDivi S Laboratories Ltd | Pharmaceuticals | ₹11,180.50 | +0.02% | 4.05 L | ₹2,97,325 Cr | $33.04B | |
| TORNTPHARMTorrent Pharmaceuticals L | Pharmaceuticals | ₹4,689.50 | +1.70% | 2.00 L | ₹1,78,727 Cr | $19.86B | |
| LAURUSLABSLaurus Labs Limited | Pharmaceuticals | ₹2,294.60 | -0.49% | 8.79 L | ₹1,24,002 Cr | $13.78B | |
| ZYDUSLIFEZydus Lifesciences Ltd | Pharmaceuticals | ₹1,200.00 | -0.24% | 7.80 L | ₹1,19,207 Cr | $13.25B | |
| DRREDDYDR. Reddy S Laboratories | Pharmaceuticals | ₹1,390.20 | -0.76% | 8.31 L | ₹1,16,145 Cr | $12.90B | |
| MANKINDMankind Pharma Limited | Pharmaceuticals | ₹2,665.00 | +1.37% | 4.56 L | ₹1,09,870 Cr | $12.21B | |
| AUROPHARMAAurobindo Pharma Ltd | Pharmaceuticals | ₹1,799.00 | -0.37% | 8.11 L | ₹1,03,298 Cr | $11.48B | |
| LUPINLupin Limited | Pharmaceuticals | ₹2,014.00 | +0.76% | 6.31 L | ₹91,916 Cr | $10.21B | |
| GLENMARKGlenmark Pharmaceuticals | Pharmaceuticals | ₹2,648.00 | +1.51% | 5.40 L | ₹74,733 Cr | $8.30B |
Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10
11/Coverage
Articles published in the last seven days, paginated by the provider.

Adani Power, LIC, Divi’s Laboratories, Hindustan Aeronautics, Adani Green Energy and others have high market capitalisation compared to the NIFTY50 bottom five stocks. But despite this, the stock is not part of the NIFTY50 index. Here’s why

| Revenue | 28,163 | 27,548 | 25,774 | 22,753 |
|---|---|---|---|---|
| Other Income | 882 | 862 | 747 | 475 |
| Total Revenue | 29,045 | 28,409 | 26,521 | 23,229 |
| Total Expenses | 23,545 | 21,589 | 20,624 | 19,008 |
| Profit Before Tax | 5,224 | 6,821 | 5,702 | 4,038 |
| Tax | 1,354 | 1,530 | 1,547 | 1,203 |
| Profit After Tax | 3,870 | 5,291 | 4,155 | 2,835 |
| EPS - Basic | 48.03 | 65.29 | 51.05 | 34.72 |
| EPS - Diluted | 48.00 | 65.24 | 51.01 | 34.69 |
This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.
On November 18, the 30-share BSE SENSEX slumped 500.38 points or 0.61% to close at 82,031.81, while the 50-share NIFTY fell by 159.45 points or 0.63% to end at 25,227.95.
Showing 1–2 of 2 articles